Analyst Sentiment Remains Bullish on CytomX Therapeutics (CTMX) Amid CX-2051 Therapy Progress

CytomX Therapeutics, Inc. (NASDAQ:CTMX) is one of the 12 best multibagger stocks to buy heading into 2026. Analyst Sentiment Remains Bullish on CytomX Therapeutics (CTMX) Amid CX-2051 Therapy Progress As of December 18, 2025, 90% of analysts are bullish on CytomX Therapeutics, Inc. (NASDAQ:CTMX), setting a median price target of $6.50. This translates into a healthy upside potential of 58.20%. On December 5, 2025, CytomX Therapeutics, Inc. (NASDAQ:CTMX) saw H.C. Wainwright reiterate its “Buy” rating wit ...